No Data
PuraPharm Reports Reduced Losses Amid Revenue Decline in 2024
PURAPHARM (01498.HK) had a revenue of 0.382 billion Hong Kong dollars in 2024, a decrease of 6.1% compared to the previous year.
On March 31, Gelonghui reported that PURAPHARM (01498.HK) achieved revenue of 0.382 billion HKD in 2024, a decrease of 6.1% year-on-year; the group recorded a net loss of 35.4 million HKD, whereas last year it recorded a net loss of 0.106 billion HKD. The loss per share attributable to ordinary shareholders of the parent company was 8.97 HKD cents. The significant reduction in the audited consolidated net loss for the year ended December 31, 2024, was mainly due to i) the decrease in impairment losses related to properties, plants and equipment, and goodwill in the group's planting segment; ii) the decrease in fair value losses of biological assets related to the group's planting segment.
Express News | PuraPharm Corp FY Gross Margin 53.7%
Express News | PuraPharm Corp FY Net Income HKD -35.4 Million
PURAPHARM: ANNOUNCEMENT OF FINAL RESULTS FOR THE YEARENDED 31 DECEMBER 2024
PURAPHARM: FURTHER POSTPONEMENT OF BOARD MEETING
